secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001485003-22-000154
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio reports Q3 net income $20.5M, announces merger with Carisma Therapeutics
--------------------------------------------------------------------------------

- Merger with Carisma: Sesen stockholders own ~41.7%, Carisma ~58.3% of combined company with ~$180M cash.
- Sesen stockholders to receive CVR for potential Roche payments related to EBI-031 asset sale.
- Combined company led by Carisma management; focus on CAR-M therapies for cancer.
- Q3 revenue $40M from Roche asset sale; net income $20.5M ($0.10 per diluted share).
- Cash $184.9M as of Sep 30, 2022; restructuring charges $10.9M from pausing Vicineum development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/0001485003-22-000154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000154/sesnform3q2022earningsrele.htm
  HTML page:      https://secwatch.observer/filing/0001485003-22-000154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer